Dynavax Technologies Corp. (NASDAQ:DVAX) shares rose 4.7% during mid-day trading on Friday . The stock traded as high as $15.00 and last traded at $14.90, with a volume of 340,288 shares trading hands. The stock had previously closed at $14.23.

DVAX has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, April 19th. JPMorgan Chase & Co. lowered shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and cut their target price for the company from $29.00 to $22.00 in a research note on Wednesday, April 27th. Royal Bank Of Canada lowered shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $48.00 to $17.00 in a research note on Wednesday, April 27th. Finally, Cowen and Company reissued a “buy” rating and set a $60.00 target price on shares of Dynavax Technologies Corp. in a research note on Thursday, April 28th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Dynavax Technologies Corp. has an average rating of “Hold” and a consensus price target of $32.20.

The stock’s market capitalization is $582.43 million. The company’s 50 day moving average is $15.08 and its 200 day moving average is $18.47.

Dynavax Technologies Corp. (NASDAQ:DVAX) last released its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. The company had revenue of $942 million for the quarter, compared to analyst estimates of $627 million. Analysts forecast that Dynavax Technologies Corp. will post ($2.90) earnings per share for the current year.

In other Dynavax Technologies Corp. news, CEO Eddie Gray purchased 2,750 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The shares were acquired at an average cost of $15.57 per share, for a total transaction of $42,817.50. Following the completion of the purchase, the chief executive officer now owns 5,050 shares of the company’s stock, valued at approximately $78,628.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Other large investors have recently bought and sold shares of the company. Swiss National Bank boosted its stake in Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 2,600 shares in the last quarter. California State Teachers Retirement System boosted its stake in Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock valued at $1,640,000 after buying an additional 1,177 shares in the last quarter. Finally, Trexquant Investment LP boosted its stake in Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock valued at $1,696,000 after buying an additional 8,911 shares in the last quarter.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.